Asian Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Targeted Drug Delivery: A Backbone for Cancer Therapy


Affiliations
1 Department of Quality Assurance., Rajarambapu College of pharmacy, Kasegaon, Maharashtra, India
     

   Subscribe/Renew Journal


Cancer is a life threatening disease which has affected globally the health of the living beings, most of the forms of cancer have reached their altitude of mortality and hence some more advanced therapies are recommended for their proper irradication. Increased population, pollution, insufficient intake of dietary supplement, functional food and neutraceuticals can cause oxidative stress and hence generation of free radicals led to cancer. Several other factors as smoking, chewing tobacco, gutka, prolong treatment of synthetic drugs, contact with certain chemicals and habit of nicotine like drugs also contribute to cancer. Increased population of cancer can affect economical, clinical and social burden. Pipeline drugs are also in their approval stage showed a distinct ray of hope in the surveillance of the patients. Surgery is considered for advanced cases but peoples have leaned towards the Ayurveda because the science of Ayurveda has added a step to curative aspects to cancer. Practice of Yoga may improve quality-of-life measures in cancer patients. The positive effects of Yoga and Ayurveda can be soothing to survivors as well and help them to deal with post-cancer distress. Targeted drug delivery has made it possible to treat deep seated tumors in a consistent manner with least amount of side effects.

Keywords

Cancer, Chemotherapy, Ayurveda, Yoga, Targeted Drug Delivery
Subscription Login to verify subscription
User
Notifications
Font Size


  • WHO-The World Health Organization's fight against cancer: strategies that prevent. Cure and care, 2007, 28.

  • American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga. Accessed at www.cancer.org/Research/CancerFactsFigures/CancerFactsFigur es/cancer-facts-figures-2012 on February 3, 2012.

  • Rajesh Dikshit, Prakash C Gupta, Chinthanie Ramasundarahettige .et al., Cancer mortality in India: a nationally representative survey.Tata Memorial Hospital, Mumbai. India 2012, 1-10.

  • American Society of Clinical Oncology. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention and Screening, Accessed at www.cancer.net/patient/ASCO%20Resources/Research%20and% 20Meetings/CCA_2009.pdf on June 8, 2012.

  • Kelly J, Thompson L, et al.Brachytherapy to treat different types of cancer: an overview of the evidence. HTA Programme: Systematic Review 4~April 2011.

  • Linehan WM, Rini BI, Yang JC., Cancer of the kidney, In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1161-1182.

  • Mulders P, Hawkins R, Nathan P, et al., Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer. 2012 Mar; 48(4):527- 37. Epub 2012 Jan 28.

  • Armitage JO, Lichter AS et al, Clinical Oncology. 4th ed. Philadelphia, Pa. Elsevier: 2008:1613-1634.

  • Keys HM, Roberts JA, et al; Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar; 92(3):744-51.

  • Kuoppala T, Maenpaa J, Tomas E, et al. surgically staged highrisk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol. 2008 Aug; 110(2):190-5.

  • Stock, C. C. (1954)., Experimental Cancer Chemotherapy. In “Advances inCancer Research” (J. P. Greenstein and A. Haddow, Eds.). Vol. 2. pp. 426–492. Academic Press, New York.

  • Masaoka A, Monden Y, et al., Follow-up study of thymoma with special reference to their clinical stage. Cancer 1981 Dec; 48(11):2485-92.

  • Santana VM, Furman WL, et al Disease control intervals in highrisk neuroblastoma. Cancer. 2008; 112:2796–2801.

  • Lippincott Williams &Wilkins, Principles and Practice of Oncology. 9th ed. Philadelphia, 2011:1760–1766.

  • Dome JS, Rodriguez-Galindo C, et al., Pediatric solid tumors. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2091–2096.

  • Motzer RJ, Bacik J, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell cancer .J Clin Oncol (2004) 22:454-63.

  • Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009; 100(11):1704-19.

  • European Medicines Agency. Vectibix: summary of product characteristics 2009. Accessed 2009 October 7. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/vectibix/ H-741-PI-en.pdf.

  • Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multideterminants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One. 2009; 4(10):e7287.

  • Georgios V. Koukourakis, Vassilios Kouloulias el al. Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review, Molecules. 2008, 13, 1897-1922.

  • European Society for Medical Oncology. Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology2012, 21(5):v55-v58.

  • http//www.actbiotech.com 23. Trondl et al., NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacology and Toxicology. 2012, 13(Suppl 1):A82.

  • Hoboken et al., Niiki Pharma Presents Data on NKP-2235, the First Highly Orally Bioavailable Gallium-Based Anti-Cancer Agent. American Association for Cancer Research (AACR), April 3, 2012.

  • http//www.niikipharma.com

  • Millie Viqueira., Commonwealth of Pennsylvania. Tobacco Settlement Investment Board Manager Objective Review. June 30, 2012.

  • Fleming, ID. Surgical therapy. In: Lenhard RE, Osteen RT, Gansler T, eds. Clinical Oncology. Atlanta, Ga: American Cancer Society, 2001:160-165.

  • Susan M. Domchek, Timothy R. Rebbeck., Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations. Issue Brief.Volume 16, Issue 2, October/November 2010.

  • Eyre HJ, Lange D, et al. Informed Decisions. 2nd Ed. Atlanta, Ga: American Cancer Society, 2002:159-170.

  • Vincenzo Violi, Nicola Pietra et al, Curative surgery for colorectal cancer. March 1998, Volume 41, 291-298.

  • El-Sayed ashraf khalil,Ibrahim fakhr et al, Cytoreductive Surgery for Advanced Epithelial Tumors of the Ovary: Technical Considerations and Outcome. Journal of the Egyptian Nat. Cancer Inst., Vol. 17, No. 3. September: 2005, 158-164.

  • E.V. Ussiri, L.E.K. Lema., Palliative Cancer Surgery. East and Central African Journal of Surgery, Volume 2005.84-87.

  • Hooda B, Lalani G, et al.Implantable Port Devices are Catheters of Choice for Administration of Chemotheapy in Pediatric Oncology Patients A Clinical Experience in Pakistan. Annals of the New York Academy of Sciences 1138: 43-46, 2008.

  • Bishara MR, Ross C. Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of saline filled breast implant after radical mastectomy for breast cancer: an unusual case presentation. Diagn Pathol. 2009 Apr.2; 4:11.

  • G. C. Prasad, manoranjan sahu, et al. CONCEPT OF CANCER IN AYURVEDA. Ancient Science of Life. Vol No. I, No.3. January 1982, Pages 172 – 176.

  • Premalatha Balachandran, Rajgopal Govindarajan., Cancer—an ayurvedic perspective. Pharmacological Research 51 (2005), 19– 30.

  • Nurgul komerik. A novel approach to cancer treatment: Photodynamic therapy. Turkish Journal of Cancer. Vol. 32/ No. 3/2002.

  • Feuerstein G. The yoga tradition: Its history, literature, philosophy and practice. Boston: Shambala, 2001.

  • Carlson, Linda E, Kamala D. Patel., et al , Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosomatic Medicine, 2003, 65(4):571-581.

  • P. Wust , B. Hildebrandt , G. Sreenivasa , et al. Hyperthermia in combined treatment of cancer.the Lancet Oncology. Volume 3. Issue 8. August 2002,487–497.

  • Brown S, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol, 2004; 5:497-508.

  • Howe JA, Demers GW, ET al.Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther. 2000 Nov; 2(5):485-95.

  • David e. Gerber. Targeted Therapies: A New Generation of Cancer Treatments American Family Physician. Volume 77, No. 3 February 1, 2008.

  • Sierra et al., Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.Molecular Cancer 2010, 1-13.

  • K. K. Jain M.D. Editorial: Targeted Drug Delivery for Cancer. Technology in Cancer Research & Treatment. Volume 4 No. 4, August (2005);311-313.

  • Michael A Firer and Gary Gellerman, Targeted drug delivery for cancer therapy: the other side of antibodies. Journal of Hematology & Oncology., 2012, 5:70.

  • Mark McClellan, Joshua Benner .et al., an accelerated pathway for targeted cancer therapies. Nature reviews | Drug Discovery. Volume 10, February 2011, 79.

  • Federica Cavallo., "Probes and Models for Imaging Diseases and Therapy”, Intensive Programme, 2012.

  • Harold J. Burstein, Jennifer J. Griggs et al., American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor–Positive Breast Cancer. journal of oncology practice .vol. 6. Issue 5,243-245.

  • Saurabh Aggarwal., Targeted cancer therapies. Nature reviews | Drug Discovery .volume 9. June 2010 , 427-428.

  • Miller RA: Treatment of B-cell lymphoma with monoclonal antiidiotype antibody. New Engl J Med (1982) 306(9):517-522.

  • Wong SF, Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. ClinTher (2005) 27(6):684-694.

  • Robert S. Kerbel, Monoclonal Antibodies in Cancer Therapy: An Overview, December 1999, Volume 18, Issue 4, 409-410.

  • Waldmann, Thomas A. "Immunotherapy: past, present and future". Nature Medicine (2003) 9(3): 269–277.

  • Casey W.Surana, Louis M.Weiner. Monoclonal antibodies for the the treatment of cancer. Seminars in cancer Biology. Volume 22. Issue 1. February 2012.,3-13


Abstract Views: 279

PDF Views: 2




  • Targeted Drug Delivery: A Backbone for Cancer Therapy

Abstract Views: 279  |  PDF Views: 2

Authors

Kumbhar Swapnil
Department of Quality Assurance., Rajarambapu College of pharmacy, Kasegaon, Maharashtra, India
Salunkhe Vijay
Department of Quality Assurance., Rajarambapu College of pharmacy, Kasegaon, Maharashtra, India
Magdum Chandrakant
Department of Quality Assurance., Rajarambapu College of pharmacy, Kasegaon, Maharashtra, India

Abstract


Cancer is a life threatening disease which has affected globally the health of the living beings, most of the forms of cancer have reached their altitude of mortality and hence some more advanced therapies are recommended for their proper irradication. Increased population, pollution, insufficient intake of dietary supplement, functional food and neutraceuticals can cause oxidative stress and hence generation of free radicals led to cancer. Several other factors as smoking, chewing tobacco, gutka, prolong treatment of synthetic drugs, contact with certain chemicals and habit of nicotine like drugs also contribute to cancer. Increased population of cancer can affect economical, clinical and social burden. Pipeline drugs are also in their approval stage showed a distinct ray of hope in the surveillance of the patients. Surgery is considered for advanced cases but peoples have leaned towards the Ayurveda because the science of Ayurveda has added a step to curative aspects to cancer. Practice of Yoga may improve quality-of-life measures in cancer patients. The positive effects of Yoga and Ayurveda can be soothing to survivors as well and help them to deal with post-cancer distress. Targeted drug delivery has made it possible to treat deep seated tumors in a consistent manner with least amount of side effects.

Keywords


Cancer, Chemotherapy, Ayurveda, Yoga, Targeted Drug Delivery

References